Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy. / Chen, Wenjia; Sadatsafavi, Mohsen; Tran, Trung N.; Murray, Ruth B.; Wong, Chong Boon Nigel; Ali, Nasloon; Ariti, Cono; Gil, Esther Garcia; Newell, Anthony; Alacqua, Marianna; Al-Ahmad, Mona; Altraja, Alan; Al-Lehebi, Riyad; Bhutani, Mohit; Bjermer, Leif; Bjerrum, Anne Sofie; Bourdin, Arnaud; Bulathsinhala, Lakmini; Von Bülow, Anna; Busby, John; Canonica, Giorgio Walter; Carter, Victoria; Christoff, George C.; Cosio, Borja G.; Costello, Richard W.; Fitzgerald, J. Mark; Fonseca, João A.; Ha Yoo, Kwang; Heaney, Liam G.; Heffler, Enrico; Hew, Mark; Hilberg, Ole; Hoyte, Flavia; Iwanaga, Takashi; Jackson, David J.; Jones, Rupert C.; Koh, Mariko Siyue; Kuna, Piotr; Larenas-Linnemann, Désirée; Lehmann, Sverre; Lehtimäki, Lauri A.; Lyu, Juntao; Mahboub, Bassam; Maspero, Jorge; Menzies-Gow, Andrew N.; Sirena, Concetta; Papadopoulos, Nikolaos; Papaioannou, Andriana I.; De Llano, Luis Pérez; Perng, Diahn Warng; Peters, Matthew; Pfeffer, Paul E.; Porsbjerg, Celeste M.; Popov, Todor A.; Rhee, Chin Kook; Salvi, Sundeep; Taillé, Camille; Taube, Christian; Torres-Duque, Carlos A.; Ulrik, Charlotte S.; Won Ra, Seung; Wang, Eileen; Wechsler, Michael E.; Price, David B.

In: Journal of Asthma and Allergy, Vol. 15, 2022, p. 1491-1510.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Chen, W, Sadatsafavi, M, Tran, TN, Murray, RB, Wong, CBN, Ali, N, Ariti, C, Gil, EG, Newell, A, Alacqua, M, Al-Ahmad, M, Altraja, A, Al-Lehebi, R, Bhutani, M, Bjermer, L, Bjerrum, AS, Bourdin, A, Bulathsinhala, L, Von Bülow, A, Busby, J, Canonica, GW, Carter, V, Christoff, GC, Cosio, BG, Costello, RW, Fitzgerald, JM, Fonseca, JA, Ha Yoo, K, Heaney, LG, Heffler, E, Hew, M, Hilberg, O, Hoyte, F, Iwanaga, T, Jackson, DJ, Jones, RC, Koh, MS, Kuna, P, Larenas-Linnemann, D, Lehmann, S, Lehtimäki, LA, Lyu, J, Mahboub, B, Maspero, J, Menzies-Gow, AN, Sirena, C, Papadopoulos, N, Papaioannou, AI, De Llano, LP, Perng, DW, Peters, M, Pfeffer, PE, Porsbjerg, CM, Popov, TA, Rhee, CK, Salvi, S, Taillé, C, Taube, C, Torres-Duque, CA, Ulrik, CS, Won Ra, S, Wang, E, Wechsler, ME & Price, DB 2022, 'Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy', Journal of Asthma and Allergy, vol. 15, pp. 1491-1510. https://doi.org/10.2147/JAA.S377174

APA

Chen, W., Sadatsafavi, M., Tran, T. N., Murray, R. B., Wong, C. B. N., Ali, N., Ariti, C., Gil, E. G., Newell, A., Alacqua, M., Al-Ahmad, M., Altraja, A., Al-Lehebi, R., Bhutani, M., Bjermer, L., Bjerrum, A. S., Bourdin, A., Bulathsinhala, L., Von Bülow, A., ... Price, D. B. (2022). Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy. Journal of Asthma and Allergy, 15, 1491-1510. https://doi.org/10.2147/JAA.S377174

Vancouver

Chen W, Sadatsafavi M, Tran TN, Murray RB, Wong CBN, Ali N et al. Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy. Journal of Asthma and Allergy. 2022;15:1491-1510. https://doi.org/10.2147/JAA.S377174

Author

Chen, Wenjia ; Sadatsafavi, Mohsen ; Tran, Trung N. ; Murray, Ruth B. ; Wong, Chong Boon Nigel ; Ali, Nasloon ; Ariti, Cono ; Gil, Esther Garcia ; Newell, Anthony ; Alacqua, Marianna ; Al-Ahmad, Mona ; Altraja, Alan ; Al-Lehebi, Riyad ; Bhutani, Mohit ; Bjermer, Leif ; Bjerrum, Anne Sofie ; Bourdin, Arnaud ; Bulathsinhala, Lakmini ; Von Bülow, Anna ; Busby, John ; Canonica, Giorgio Walter ; Carter, Victoria ; Christoff, George C. ; Cosio, Borja G. ; Costello, Richard W. ; Fitzgerald, J. Mark ; Fonseca, João A. ; Ha Yoo, Kwang ; Heaney, Liam G. ; Heffler, Enrico ; Hew, Mark ; Hilberg, Ole ; Hoyte, Flavia ; Iwanaga, Takashi ; Jackson, David J. ; Jones, Rupert C. ; Koh, Mariko Siyue ; Kuna, Piotr ; Larenas-Linnemann, Désirée ; Lehmann, Sverre ; Lehtimäki, Lauri A. ; Lyu, Juntao ; Mahboub, Bassam ; Maspero, Jorge ; Menzies-Gow, Andrew N. ; Sirena, Concetta ; Papadopoulos, Nikolaos ; Papaioannou, Andriana I. ; De Llano, Luis Pérez ; Perng, Diahn Warng ; Peters, Matthew ; Pfeffer, Paul E. ; Porsbjerg, Celeste M. ; Popov, Todor A. ; Rhee, Chin Kook ; Salvi, Sundeep ; Taillé, Camille ; Taube, Christian ; Torres-Duque, Carlos A. ; Ulrik, Charlotte S. ; Won Ra, Seung ; Wang, Eileen ; Wechsler, Michael E. ; Price, David B. / Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy. In: Journal of Asthma and Allergy. 2022 ; Vol. 15. pp. 1491-1510.

Bibtex

@article{5c5d44bce82b4aa6b4e67e6ab88b5717,
title = "Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy",
abstract = "Background: Many severe asthma patients with high oral corticosteroid exposure (HOCS) often do not initiate biologics despite being eligible. This study aimed to compare the characteristics of severe asthma patients with HOCS who did and did not initiate biologics. Methods: Baseline characteristics of patients with HOCS (long-term maintenance OCS therapy for at least 1 year, or ≥4 courses of steroid bursts in a year) from the International Severe Asthma Registry (ISAR; https://isaregistries.org/), who initiated or did not initiate biologics (anti-lgE, anti-IL5/5R or anti-IL4R), were described at the time of biologic initiation or registry enrolment. Statistical relationships were tested using Pearson's chi-squared tests for categorical variables, and t-tests for continuous variables, adjusting for potential errors in multiple comparisons. Results: Between January 2015 and February 2021, we identified 1412 adult patients with severe asthma from 19 countries that met our inclusion criteria of HOCS, of whom 996 (70.5%) initiated a biologic and 416 (29.5%) did not. The frequency of biologic initiation varied across geographical regions. Those who initiated a biologic were more likely to have higher blood eosinophil count (483 vs 399 cells/µL, p=0.003), serious infections (49.0% vs 13.3%, p<0.001), nasal polyps (35.2% vs 23.6%, p<0.001), airflow limitation (56.8% vs 51.8%, p=0.013), and uncontrolled asthma (80.8% vs 73.2%, p=0.004) despite greater conventional treatment adherence than those who did not start a biologic. Both groups had similar annual asthma exacerbation rates in the previous 12 months (5.7 vs 5.3, p=0.147). Conclusion: Around one third of severe HOCS asthma patients did not receive biologics despite a similar high burden of asthma exacerbations as those who initiated a biologic therapy. Other disease characteristics such as eosinophilic phenotype, serious infectious events, nasal polyps, airflow limitation and lack of asthma control appear to dictate biologic use.",
keywords = "Biologics, Patient characteristics, Real-world, Severe asthma, Treatment pattern",
author = "Wenjia Chen and Mohsen Sadatsafavi and Tran, {Trung N.} and Murray, {Ruth B.} and Wong, {Chong Boon Nigel} and Nasloon Ali and Cono Ariti and Gil, {Esther Garcia} and Anthony Newell and Marianna Alacqua and Mona Al-Ahmad and Alan Altraja and Riyad Al-Lehebi and Mohit Bhutani and Leif Bjermer and Bjerrum, {Anne Sofie} and Arnaud Bourdin and Lakmini Bulathsinhala and {Von B{\"u}low}, Anna and John Busby and Canonica, {Giorgio Walter} and Victoria Carter and Christoff, {George C.} and Cosio, {Borja G.} and Costello, {Richard W.} and Fitzgerald, {J. Mark} and Fonseca, {Jo{\~a}o A.} and {Ha Yoo}, Kwang and Heaney, {Liam G.} and Enrico Heffler and Mark Hew and Ole Hilberg and Flavia Hoyte and Takashi Iwanaga and Jackson, {David J.} and Jones, {Rupert C.} and Koh, {Mariko Siyue} and Piotr Kuna and D{\'e}sir{\'e}e Larenas-Linnemann and Sverre Lehmann and Lehtim{\"a}ki, {Lauri A.} and Juntao Lyu and Bassam Mahboub and Jorge Maspero and Menzies-Gow, {Andrew N.} and Concetta Sirena and Nikolaos Papadopoulos and Papaioannou, {Andriana I.} and {De Llano}, {Luis P{\'e}rez} and Perng, {Diahn Warng} and Matthew Peters and Pfeffer, {Paul E.} and Porsbjerg, {Celeste M.} and Popov, {Todor A.} and Rhee, {Chin Kook} and Sundeep Salvi and Camille Taill{\'e} and Christian Taube and Torres-Duque, {Carlos A.} and Ulrik, {Charlotte S.} and {Won Ra}, Seung and Eileen Wang and Wechsler, {Michael E.} and Price, {David B.}",
note = "Publisher Copyright: {\textcopyright} 2022 Chen et al. This work is published and licensed by Dove Medical Press Limited.",
year = "2022",
doi = "10.2147/JAA.S377174",
language = "English",
volume = "15",
pages = "1491--1510",
journal = "Journal of Asthma and Allergy",
issn = "1178-6965",
publisher = "Dove Medical Press Ltd",

}

RIS

TY - JOUR

T1 - Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

AU - Chen, Wenjia

AU - Sadatsafavi, Mohsen

AU - Tran, Trung N.

AU - Murray, Ruth B.

AU - Wong, Chong Boon Nigel

AU - Ali, Nasloon

AU - Ariti, Cono

AU - Gil, Esther Garcia

AU - Newell, Anthony

AU - Alacqua, Marianna

AU - Al-Ahmad, Mona

AU - Altraja, Alan

AU - Al-Lehebi, Riyad

AU - Bhutani, Mohit

AU - Bjermer, Leif

AU - Bjerrum, Anne Sofie

AU - Bourdin, Arnaud

AU - Bulathsinhala, Lakmini

AU - Von Bülow, Anna

AU - Busby, John

AU - Canonica, Giorgio Walter

AU - Carter, Victoria

AU - Christoff, George C.

AU - Cosio, Borja G.

AU - Costello, Richard W.

AU - Fitzgerald, J. Mark

AU - Fonseca, João A.

AU - Ha Yoo, Kwang

AU - Heaney, Liam G.

AU - Heffler, Enrico

AU - Hew, Mark

AU - Hilberg, Ole

AU - Hoyte, Flavia

AU - Iwanaga, Takashi

AU - Jackson, David J.

AU - Jones, Rupert C.

AU - Koh, Mariko Siyue

AU - Kuna, Piotr

AU - Larenas-Linnemann, Désirée

AU - Lehmann, Sverre

AU - Lehtimäki, Lauri A.

AU - Lyu, Juntao

AU - Mahboub, Bassam

AU - Maspero, Jorge

AU - Menzies-Gow, Andrew N.

AU - Sirena, Concetta

AU - Papadopoulos, Nikolaos

AU - Papaioannou, Andriana I.

AU - De Llano, Luis Pérez

AU - Perng, Diahn Warng

AU - Peters, Matthew

AU - Pfeffer, Paul E.

AU - Porsbjerg, Celeste M.

AU - Popov, Todor A.

AU - Rhee, Chin Kook

AU - Salvi, Sundeep

AU - Taillé, Camille

AU - Taube, Christian

AU - Torres-Duque, Carlos A.

AU - Ulrik, Charlotte S.

AU - Won Ra, Seung

AU - Wang, Eileen

AU - Wechsler, Michael E.

AU - Price, David B.

N1 - Publisher Copyright: © 2022 Chen et al. This work is published and licensed by Dove Medical Press Limited.

PY - 2022

Y1 - 2022

N2 - Background: Many severe asthma patients with high oral corticosteroid exposure (HOCS) often do not initiate biologics despite being eligible. This study aimed to compare the characteristics of severe asthma patients with HOCS who did and did not initiate biologics. Methods: Baseline characteristics of patients with HOCS (long-term maintenance OCS therapy for at least 1 year, or ≥4 courses of steroid bursts in a year) from the International Severe Asthma Registry (ISAR; https://isaregistries.org/), who initiated or did not initiate biologics (anti-lgE, anti-IL5/5R or anti-IL4R), were described at the time of biologic initiation or registry enrolment. Statistical relationships were tested using Pearson's chi-squared tests for categorical variables, and t-tests for continuous variables, adjusting for potential errors in multiple comparisons. Results: Between January 2015 and February 2021, we identified 1412 adult patients with severe asthma from 19 countries that met our inclusion criteria of HOCS, of whom 996 (70.5%) initiated a biologic and 416 (29.5%) did not. The frequency of biologic initiation varied across geographical regions. Those who initiated a biologic were more likely to have higher blood eosinophil count (483 vs 399 cells/µL, p=0.003), serious infections (49.0% vs 13.3%, p<0.001), nasal polyps (35.2% vs 23.6%, p<0.001), airflow limitation (56.8% vs 51.8%, p=0.013), and uncontrolled asthma (80.8% vs 73.2%, p=0.004) despite greater conventional treatment adherence than those who did not start a biologic. Both groups had similar annual asthma exacerbation rates in the previous 12 months (5.7 vs 5.3, p=0.147). Conclusion: Around one third of severe HOCS asthma patients did not receive biologics despite a similar high burden of asthma exacerbations as those who initiated a biologic therapy. Other disease characteristics such as eosinophilic phenotype, serious infectious events, nasal polyps, airflow limitation and lack of asthma control appear to dictate biologic use.

AB - Background: Many severe asthma patients with high oral corticosteroid exposure (HOCS) often do not initiate biologics despite being eligible. This study aimed to compare the characteristics of severe asthma patients with HOCS who did and did not initiate biologics. Methods: Baseline characteristics of patients with HOCS (long-term maintenance OCS therapy for at least 1 year, or ≥4 courses of steroid bursts in a year) from the International Severe Asthma Registry (ISAR; https://isaregistries.org/), who initiated or did not initiate biologics (anti-lgE, anti-IL5/5R or anti-IL4R), were described at the time of biologic initiation or registry enrolment. Statistical relationships were tested using Pearson's chi-squared tests for categorical variables, and t-tests for continuous variables, adjusting for potential errors in multiple comparisons. Results: Between January 2015 and February 2021, we identified 1412 adult patients with severe asthma from 19 countries that met our inclusion criteria of HOCS, of whom 996 (70.5%) initiated a biologic and 416 (29.5%) did not. The frequency of biologic initiation varied across geographical regions. Those who initiated a biologic were more likely to have higher blood eosinophil count (483 vs 399 cells/µL, p=0.003), serious infections (49.0% vs 13.3%, p<0.001), nasal polyps (35.2% vs 23.6%, p<0.001), airflow limitation (56.8% vs 51.8%, p=0.013), and uncontrolled asthma (80.8% vs 73.2%, p=0.004) despite greater conventional treatment adherence than those who did not start a biologic. Both groups had similar annual asthma exacerbation rates in the previous 12 months (5.7 vs 5.3, p=0.147). Conclusion: Around one third of severe HOCS asthma patients did not receive biologics despite a similar high burden of asthma exacerbations as those who initiated a biologic therapy. Other disease characteristics such as eosinophilic phenotype, serious infectious events, nasal polyps, airflow limitation and lack of asthma control appear to dictate biologic use.

KW - Biologics

KW - Patient characteristics

KW - Real-world

KW - Severe asthma

KW - Treatment pattern

U2 - 10.2147/JAA.S377174

DO - 10.2147/JAA.S377174

M3 - Journal article

C2 - 36303891

AN - SCOPUS:85141030684

VL - 15

SP - 1491

EP - 1510

JO - Journal of Asthma and Allergy

JF - Journal of Asthma and Allergy

SN - 1178-6965

ER -

ID: 340847480